Arshad M. Khanani, MD
Show Description +
Arshad M. Khanani, MD, reviews the HAWK/HARRIER phase 3 studies on the efficacy and safety of brolucizumab (RTH258, Novartis) versus aflibercept (Eylea, Regeneron) in the treatment of neovascular age-related macular degeneration (nAMD).
Posted: 7/20/2018
Arshad M. Khanani, MD
Arshad M. Khanani, MD, reviews the HAWK/HARRIER phase 3 studies on the efficacy and safety of brolucizumab (RTH258, Novartis) versus aflibercept (Eylea, Regeneron) in the treatment of neovascular age-related macular degeneration (nAMD).
Posted: 7/20/2018
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of ASRS: 2018.
Please log in to leave a comment.